Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration
Claudia Taipale,1,2 Ilkka Laine,1,3 Raimo Tuuminen1,3 1Helsinki Retina Research Group, Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland; 2Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland; 3Department of Ophthalmology, Kymenlaakso Central Hospital,...
Saved in:
Main Authors: | Taipale C, Laine I, Tuuminen R |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2018
|
Subjects: | |
Online Access: | https://doaj.org/article/2e6ada86c0e44f06923a94e7506226bf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
by: Khanani AM, et al.
Published: (2019) -
Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
by: Garweg JG
Published: (2019) -
Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update
by: Patel PJ, et al.
Published: (2017) -
Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
by: Amoaku W, et al.
Published: (2018) -
Physician, patient, and caregiver experience of different wet age-related macular degeneration anti-VEGF treatment regimens in Japan: a qualitative assessment
by: Iida T, et al.
Published: (2016)